www射-国产免费一级-欧美福利-亚洲成人福利-成人一区在线观看-亚州成人

USEUROPEAFRICAASIA 中文雙語Fran?ais
Business
Home / Business / Companies

Pharma boss likes a fit lifestyle

By Liu Jie | China Daily | Updated: 2013-07-11 07:30

Pharma boss likes a fit lifestyle

A laboratory in China Novartis Institutes for BioMedical Research in Shanghai, The facility is Switzerland-based Novartis AG's third-largest research and development center in the world. [Photo / Provided to China Daily]

Pharma boss likes a fit lifestyle

CEO likens sport discipline to rigor of global business

As a former competitive swimmer, the dedication Joseph Jimenez had to display on a daily basis helps in his current position as chief executive officer of pharmaceutical giant Novartis AG.

"Being a competitive swimmer, you are taught the discipline of working hard, then training for the big event, achieving a result and then celebrating once you win," he said. "That's very close to what we do at Novartis. We work very hard toward a goal. We set the objective then we deliver it. And then we try to celebrate - but only for a short time - until we set the next goal."

In addition, strong mettle, courage and consistency are characteristics required in both top-level swimming and business.

Upon joining Novartis in 2007 as division head of the consumer health unit - the over-the-counter drugs business - Jimenez had no scientific or pharmaceutical background but did possess rich experience in the consumer goods industry and business degrees from Stanford University and University of California, Berkeley.

He discovered a fellow employee with a science background who was good at communicating clearly on the topic of complicated pharmaceuticals and invited him to his office on many early mornings to go over in detail every drug that Switzerland-based Novartis produced: the biology of the disease each one treated and the mechanism through which they worked, just like morning training in the world of sports.

"I needed to win the respect of the company's scientists and, ultimately, I had to understand the products so that we, together, could make some key decisions," he said.

In 2007, Jimenez was appointed to lead the pharmaceuticals division - a core business of Novartis engaged in innovative drugs. At the time the company was facing the challenge of stricter regulations in the United States and Europe and medical policies in various nations were changing. The Novartis board wanted to bring a fresh eye to the issues.

Because of his success in leading the transformation of the pharmaceutical portfolio to balance mass market and specialty products and significantly increasing the percentage of sales from newly launched products, Jimenez was promoted to the CEO position in 2010. His job was to manage the medical regimes of five business units - pharmaceuticals, eye care, generics, vaccines and diagnostics, as well as over-the-counter drugs and animal health.

At the moment Jimenez and the industry in general are facing a trio of huge challenges: the expiry of patents on certain highly popular drugs, price-cutting pressure from governments around the world and the global economic slowdown.

What is known in the industry as the "patent cliff" means after patent expiration of a blockbuster drug, other companies can produce a generic with the same essential chemicals at a much lower price to capture a high market percentage. Blockbuster drugs are defined as medicines that provide revenues of more than $1 billion sales per year. High profits are required to pay for the high costs of research and development required by the pharmaceutical industry.

For more than a decade, the top-selling Novartis product had been Diovan, an anti-hypertensive medicine. People who need it should take it every day. In 2011 and 2012, the patent on Diovan in Europe and the United States expired, and around a dozen drugmakers began manufacturing generic versions at much lower prices. In 2007, the Novartis pharmaceuticals division as a whole had revenues of $24 billion, of which $5 billion came from sales of Diovan.

Novartis is not alone in facing the issue. The patent for US-based Pfizer Inc's Lipitor, the best-selling prescription drug in history, ended in 2011. Analysts said Lipitor sales will decline from about $11 billion in 2009 and 2010 to just above $3 billion in 2015.

IMS Health, a healthcare information provider, forecasts that by 2016 patent expirations will have caused a loss of $106 billion in sales from branded drugs over the previous five years, with the heaviest burdens occurring in 2012 and 2013.

To deal with the problem, innovation-centered drugmakers are taking various measures, such as further enhancing their R&D strengths and expanding their own generic business. US drugmaker Eli Lilly and Co's Chairman, President and CEO John C. Lechleiter said his company would continue to put 20 percent of its sales into R&D in the coming years. Pfizer announced a $545 million generic joint venture deal with Zhejiang Hisun Pharma last February, saying that it wants to keep pursuing "opportunities" in China and India to expand its portfolio of generic drugs.

Previous 1 2 Next

Most Viewed in 24 Hours
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
 
主站蜘蛛池模板: 久久久久久网址 | 亚洲欧美在线免费观看 | 日本不卡一区二区三区在线观看 | 日本黄页网站在线观看 | 欧美大尺度免费一级特黄 | 看v片 | avtom影院入口永久在线 | 久99久精品视频免费观看v | 国产综合在线观看视频 | 欧美亚洲另类久久综合 | 美美女高清毛片视频免费观看 | 久久免费视频2 | 国产黄色大片网站 | 国产精品九九久久一区hh | 久久成人在线 | 深爱激情五月网 | 国产成人精品亚洲77美色 | 在线观看精品国产 | 亚洲综合第一页 | 热99re久久国超精品首页 | 日本wwww视频 | 99精品福利 | 亚洲综合色dddd26 | 美女操穴视频 | 日韩一级片在线播放 | 可以免费看黄的网站 | 亚洲国产成+人+综合 | 国产精品二区三区 | 亚洲影院手机版777点击进入影院 | 大臿蕉香蕉大视频成人 | 免费一级a毛片在线播放视 免费一级α片在线观看 | 国内精品久久国产大陆 | 91资源在线播放 | 国产精品亚洲一区在线播放 | 伊人久久综合热青草 | 欧美一级aa天码毛片 | 欧美videofree性欧美另类 | 台湾香港澳门三级在线 | 国产一区二区三区四区在线 | 久久国产成人亚洲精品影院老金 | 狠狠色丁香婷婷久久综合考虑 |